178 related articles for article (PubMed ID: 12845514)
41. Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy.
Sigsgaard T; Herrstedt J; Andersen LJ; Havsteen H; Langer SW; Kjaerbøl AG; Lund H; Kjaer M; Dombernowsky P
Br J Cancer; 1999 May; 80(3-4):412-8. PubMed ID: 10408847
[TBL] [Abstract][Full Text] [Related]
42. An all oral antiemetic regimen for patients undergoing high-dose chemotherapy with peripheral blood stem cell transplant.
Frakes LA; Brehm TL; Kosty MP; Miller WE; McMillan RL; Mason J; Meisenberg BR
Bone Marrow Transplant; 1997 Sep; 20(6):473-8. PubMed ID: 9313880
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting.
Howell J; Smeets J; Drenth HJ; Gill D
J Oncol Pharm Pract; 2009 Dec; 15(4):223-31. PubMed ID: 19304880
[TBL] [Abstract][Full Text] [Related]
44. Granisetron: the second serotonin-receptor antagonist.
Adams VR; Valley AW
Ann Pharmacother; 1995 Dec; 29(12):1240-51. PubMed ID: 8672830
[TBL] [Abstract][Full Text] [Related]
45. Low-dose granisetron for prophylaxis of acute chemotherapy-induced nausea and vomiting: a pilot study.
Moreno J; Sahade M; del Giglio A
Support Care Cancer; 2005 Oct; 13(10):850-3. PubMed ID: 15838618
[TBL] [Abstract][Full Text] [Related]
46. Outcomes of antiemetic prophylaxis in children undergoing bone marrow transplantation.
Kusnierczyk NM; Saunders EF; Dupuis LL
Bone Marrow Transplant; 2002 Jul; 30(2):119-24. PubMed ID: 12132051
[TBL] [Abstract][Full Text] [Related]
47. Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria.
Raftopoulos H; Boccia R; Cooper W; O'Boyle E; Gralla RJ
Future Oncol; 2015 Sep; 11(18):2541-51. PubMed ID: 26289588
[TBL] [Abstract][Full Text] [Related]
48. Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation.
Spitzer TR; Friedman CJ; Bushnell W; Frankel SR; Raschko J
Bone Marrow Transplant; 2000 Jul; 26(2):203-10. PubMed ID: 10918432
[TBL] [Abstract][Full Text] [Related]
49. [Clinical evaluation of 2-mg granisetron tablet for nausea and vomiting induced by anticancer drugs including cisplatin].
Yoshiya N; Kodama S; Aoki Y; Takahashi T; Honma S; Endo M; Tokunaga A; Takeuchi Y; Hanaoka J; Maruhashi T; Oshima T; Tanaka K; Furue H
Gan To Kagaku Ryoho; 1997 Jul; 24(9):1141-7. PubMed ID: 9239168
[TBL] [Abstract][Full Text] [Related]
50. Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer.
Fujiwara S; Terai Y; Tsunetoh S; Sasaki H; Kanemura M; Ohmichi M
J Gynecol Oncol; 2015 Oct; 26(4):311-9. PubMed ID: 26197776
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
[TBL] [Abstract][Full Text] [Related]
52. [Granisetron oral phase III clinical trial--study on the inhibitory effect of granisetron for nausea/vomiting induced by chemotherapy for tumors in the hematopoietic organs].
Hiraoka A; Masaoka T; Nagai K; Kakishita E; Oshiba S; Kageyama T; Okuda K; Tatsumi N; Uchino H; Matsuzawa Y
Gan To Kagaku Ryoho; 1993 Sep; 20(12):1835-41. PubMed ID: 8397489
[TBL] [Abstract][Full Text] [Related]
53. Granisetron: an update on its clinical use in the management of nausea and vomiting.
Aapro M
Oncologist; 2004; 9(6):673-86. PubMed ID: 15561811
[TBL] [Abstract][Full Text] [Related]
54. Is ondansetron more effective than granisetron for chemotherapy-induced nausea and vomiting? A review of comparative trials.
Vrabel M
Clin J Oncol Nurs; 2007 Dec; 11(6):809-13. PubMed ID: 18063539
[TBL] [Abstract][Full Text] [Related]
55. Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial.
Walsh T; Morris AK; Holle LM; Callander N; Bradshaw P; Valley AW; Clark G; Freytes CO
Bone Marrow Transplant; 2004 Dec; 34(11):963-8. PubMed ID: 15489869
[TBL] [Abstract][Full Text] [Related]
56. [Clinical evaluation of granisetron hydrochloride against nausea and vomiting induced by anticancer drugs for gynecological malignant tumors].
Kitada M; Sawaragi I
Gan To Kagaku Ryoho; 1996 Jan; 23(1):87-91. PubMed ID: 8546476
[TBL] [Abstract][Full Text] [Related]
57. Antiemetic agents.
Wilkes G
Oncology (Williston Park); 2007 Jul; 21(8 Suppl):48. PubMed ID: 17844897
[No Abstract] [Full Text] [Related]
58. [Prevention and treatment of postoperative nausea and vomiting with 5-HT3-receptor blockers].
Alon E; Biro P
Anasthesiol Intensivmed Notfallmed Schmerzther; 1996 May; 31(4):200-4. PubMed ID: 8704077
[TBL] [Abstract][Full Text] [Related]
59. First choice for radiation-induced nausea and vomiting--the efficacy and safety of granisetron.
Goldsmith B
Acta Oncol; 2004 Sep; 43 Suppl 15():19-22. PubMed ID: 15370626
[No Abstract] [Full Text] [Related]
60. Further studies of the antiemetic activity of granisetron against whole body X-irradiation or cisplatin-induced emesis in the ferret.
Marr HE; Davey PT; Boyle EA; Blower PR
Pharmacology; 1994 May; 48(5):283-92. PubMed ID: 8016189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
